Outcome ratio – ATRX http://atrx.net/ Fri, 26 Nov 2021 06:41:11 +0000 en-US hourly 1 https://wordpress.org/?v=5.8 https://atrx.net/wp-content/uploads/2021/10/icon-3-120x120.png Outcome ratio – ATRX http://atrx.net/ 32 32 Is MDI Energia SA (WSE: MDI) high quality stock to own? https://atrx.net/is-mdi-energia-sa-wse-mdi-high-quality-stock-to-own/ Fri, 26 Nov 2021 04:49:05 +0000 https://atrx.net/is-mdi-energia-sa-wse-mdi-high-quality-stock-to-own/ One of the best investments we can make is in our own knowledge and skills. With that in mind, this article will discuss how we can use Return on Equity (ROE) to better understand a business. We will use ROE to examine MDI Energia SA (WSE: MDI), through a worked example. Return on equity or […]]]>

One of the best investments we can make is in our own knowledge and skills. With that in mind, this article will discuss how we can use Return on Equity (ROE) to better understand a business. We will use ROE to examine MDI Energia SA (WSE: MDI), through a worked example.

Return on equity or ROE is an important factor for a shareholder to consider because it tells them how effectively their capital is being reinvested. In simpler terms, it measures a company’s profitability relative to equity.

See our latest review for MDI Energia

How do you calculate return on equity?

ROE can be calculated using the formula:

Return on equity = Net income (from continuing operations) ÷ Equity

So, based on the above formula, the ROE of MDI Energia is:

20% = zł6,7m zł34m (Based on the last twelve months up to September 2021).

The “return” is the annual profit. This means that for every PLN 1 value of equity, the company generated a profit of PLN 0.20.

Does MDI Energia have a good return on equity?

By comparing a company’s ROE with its industry average, we can get a quick measure of its quality. It is important to note that this measure is far from perfect, as companies differ considerably within a single industry classification. Fortunately, MDI Energia has an above-average ROE (9.5%) for the renewable energy sector.

WSE: MDI Return on Equity November 26, 2021

This is what we love to see. That said, high ROE doesn’t always indicate high profitability. Besides changes in net income, high ROE can also be the result of high leverage to equity, which indicates risk. Our risk dashboard should include the 3 risks that we have identified for MDI Energia.

Why You Should Consider Debt When Looking At ROE

Businesses generally need to invest money to increase their profits. This liquidity can come from the issuance of shares, retained earnings or debt. In the case of the first and second options, the ROE will reflect this use of cash, for growth. In the latter case, the debt necessary for growth will increase returns, but will have no impact on equity. So, using debt can improve ROE, but with added risk in stormy weather, metaphorically speaking.

Combine MDI Energia’s debt and its 20% return on equity

MDI Energia uses a large amount of debt to increase returns. Its debt ratio is 1.69. While its ROE is respectable, it should be borne in mind that there is usually a limit on how much debt a business can use. Investors should think carefully about how a business will perform if it weren’t able to borrow so easily, as credit markets change over time.

Conclusion

Return on equity is a way to compare the business quality of different companies. In our books, the highest quality companies have a high return on equity, despite low leverage. If two companies have the same ROE, I would generally prefer the one with the least amount of debt.

But when a company is of high quality, the market often offers it up to a price that reflects that. The rate at which earnings are likely to grow, relative to earnings growth expectations reflected in the current price, must also be considered. Check out MDI Energia’s past earnings growth by looking at this visualization of past earnings, revenue, and cash flow.

Sure MDI Energia may not be the best stock to buy. So you might want to see this free collection of other companies with high ROE and low leverage.

This Simply Wall St article is general in nature. We provide commentary based on historical data and analyst forecasts using only unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell shares and does not take into account your goals or your financial situation. Our aim is to bring you long-term, targeted analysis based on fundamental data. Note that our analysis may not take into account the latest announcements from price sensitive companies or qualitative documents. Simply Wall St has no position in the mentioned stocks.

Do you have any feedback on this item? Are you worried about the content? Get in touch with us directly. You can also send an email to the editorial team (at) simplywallst.com.


Source link

]]>
Telenor’s Dtac to merge with True in Thailand in $ 8.6 billion deal https://atrx.net/telenors-dtac-to-merge-with-true-in-thailand-in-8-6-billion-deal/ Mon, 22 Nov 2021 05:08:44 +0000 https://atrx.net/telenors-dtac-to-merge-with-true-in-thailand-in-8-6-billion-deal/ CP Group and Telenor have agreed to explore the merger of their mobile operators True and dtac in an $ 8.6 billion deal. The new company intends to raise venture capital funds with partners of $ 100-200 million to invest in promising digital startups focused on new products and services for the benefit of all […]]]>

CP Group and Telenor have agreed to explore the merger of their mobile operators True and dtac in an $ 8.6 billion deal.

The new company intends to raise venture capital funds with partners of $ 100-200 million to invest in promising digital startups focused on new products and services for the benefit of all Thai consumers.

The transaction will consist of a conditional voluntary takeover bid (VTO) for all of the outstanding shares of dtac and True, followed by the merger of dtac and True creating a new company.

The VTO price for dtac will be 47.76 THB, which is a 25% premium over the one-month VWAP for dtac shares, and the VTO price of True will be 5.09 THB, which is a 25% premium over a month’s VWAP for Real Shares.

The agreed exchange ratio is 10.221 true shares per dtac share. The result of the VTO will determine the final equalized percentage of ownership between CP Group and Telenor Group.

All dtac and True shareholders will have the choice of participating in the takeover bid or continuing as shareholders of the combined listed company in Thailand.

CP Group and Telenor Group recognize that not all shareholders may want to participate and offer an attractive premium cash alternative. The merged company faces a difficult operating environment.

Dtac reported a turnover of NOK 5,335 million in the second quarter of 2021 compared to NOK 6,013 million in the second quarter of 2020. Dtac’s investments increased to NOK 977 million from NOK 432 million.

Dtac’s subscription and traffic revenues fell 2% and EBITDA fell 1% in the second quarter. Dtac said the number of subscriptions increased from 164,000 to 19.249 million.

The current operations of True and dtac will run their activities independently until the transaction is completed. The transaction will be subject to the approvals of the boards of directors and relevant shareholders and customary regulatory approvals.


Source link

]]>
Should we be pleased with the ROE of Diös Fastigheter AB (publ) (STO: DIOS) of 18%? https://atrx.net/should-we-be-pleased-with-the-roe-of-dios-fastigheter-ab-publ-sto-dios-of-18/ Sat, 20 Nov 2021 07:30:46 +0000 https://atrx.net/should-we-be-pleased-with-the-roe-of-dios-fastigheter-ab-publ-sto-dios-of-18/ Many investors are still educating themselves about the various metrics that can be useful when analyzing a stock. This article is for those who want to learn more about return on equity (ROE). To keep the lesson practical, we will use the ROE to better understand Diös Fastigheter AB (publ) (STO: DIOS). Return on equity […]]]>

Many investors are still educating themselves about the various metrics that can be useful when analyzing a stock. This article is for those who want to learn more about return on equity (ROE). To keep the lesson practical, we will use the ROE to better understand Diös Fastigheter AB (publ) (STO: DIOS).

Return on equity or ROE is a key metric used to assess the efficiency with which the management of a business is using business capital. In other words, it is a profitability ratio that measures the rate of return on capital contributed by the shareholders of the company.

Check out our latest review for Diös Fastigheter

How to calculate return on equity?

Return on equity can be calculated using the formula:

Return on equity = Net income (from continuing operations) ÷ Equity

So, based on the above formula, Diös Fastigheter’s ROE is:

18% = kr1.8b ÷ kr10b (based on the last twelve months up to September 2021).

The “return” is the annual profit. This therefore means that for each SEK1 of the investments of its shareholder, the company generates a profit of SEK0.18.

Does Diös Fastigheter have a good return on equity?

By comparing a company’s ROE with its industry average, we can get a quick measure of its quality. However, this method is only useful as a rough check, as companies differ a lot within the same industry classification. Fortunately, Diös Fastigheter has an above-average ROE (14%) for the real estate industry.

OM: DIOS Return on Equity November 20, 2021

This is clearly a positive point. That said, high ROE doesn’t always indicate high profitability. Besides changes in net income, high ROE can also be the result of high leverage to equity, which indicates risk. To know the 4 risks that we have identified for Diös Fastigheter, visit our risk dashboard free of charge.

What is the impact of debt on return on equity?

Almost all businesses need money to invest in the business, to increase their profits. This liquidity can come from the issuance of shares, retained earnings or debt. In the first and second cases, the ROE will reflect this use of cash for investing in the business. In the latter case, the debt used for growth will improve returns, but will not affect total equity. In this way, the use of debt will increase the ROE, even if the basic economy of the business remains the same.

Diös Fastigheter’s debt and its 18% ROE

Diös Fastigheter clearly uses a high amount of debt to increase returns, as he has a debt to equity ratio of 1.45. While his ROE is quite respectable, the amount of debt the company currently carries is not ideal. Debt comes with additional risk, so it’s only really worth it when a business is making decent returns from it.

Summary

Return on equity is a useful indicator of a company’s ability to generate profits and return them to shareholders. A business that can earn a high return on equity without going into debt can be considered a high quality business. If two companies have roughly the same level of debt to equity and one has a higher ROE, I would generally prefer the one with a higher ROE.

But ROE is only one piece of a bigger puzzle, as high-quality companies often trade at high earnings multiples. Especially important to consider are the growth rates of earnings, relative to expectations reflected in the share price. So I think it’s worth checking this out free analyst forecast report for the company.

If you would rather consult with another company – one with potentially superior finances – then don’t miss this free list of interesting companies, which have a HIGH return on equity and low leverage.

This Simply Wall St article is general in nature. We provide commentary based on historical data and analyst forecasts using only unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell shares and does not take into account your goals or your financial situation. Our aim is to bring you long-term, targeted analysis based on fundamental data. Note that our analysis may not take into account the latest announcements from price sensitive companies or qualitative documents. Simply Wall St does not have any position in the mentioned stocks.

Do you have any feedback on this item? Are you worried about the content? Get in touch with us directly. You can also send an email to the editorial team (at) simplywallst.com.


Source link

]]>
Experts say British politics are undergoing a post-neoliberal shift. They are wrong https://atrx.net/experts-say-british-politics-are-undergoing-a-post-neoliberal-shift-they-are-wrong/ Thu, 18 Nov 2021 10:17:27 +0000 https://atrx.net/experts-say-british-politics-are-undergoing-a-post-neoliberal-shift-they-are-wrong/ Shortly before the 1979 general election, Labor Prime Minister Jim Callaghan warned of a “radical change in policy” in favor of Margaret Thatcher’s anti-social agenda. There is today a lot of speculation of a similar “philosophical shift” from the anti-state and neoliberal policies of the past decade, a enhanced view by last month’s budget. The […]]]>

Shortly before the 1979 general election, Labor Prime Minister Jim Callaghan warned of a “radical change in policy” in favor of Margaret Thatcher’s anti-social agenda. There is today a lot of speculation of a similar “philosophical shift” from the anti-state and neoliberal policies of the past decade, a enhanced view by last month’s budget.

The last century has already seen two tectonic reversals in the government of philosophy. The first was the post-1945 social democratic experience and the second was the Thatcherite counterrevolution of the early 1980s. It is this second type of politics that experts say is on the way out.

There is no doubt that COVID-19 has had a galvanizing impact on the role of government, with elements of the pro-market and anti-state rulebook being torn apart in favor of an unprecedented, in peacetime, state response to support jobs and incomes, and an increase in public spending and tax levels. But do these changes herald a more fundamental change of direction or a simple political adjustment, a temporary and pragmatic response to a national crisis? As Robert E Lucas, one of Chicago’s post-1980s market revolution high priests, observed, “We are all Keynesians in a tug-of-war.”

There is no better litmus test of whether we are ready for a new governance paradigm and a better post-COVID society than what is happening to deep-rooted British society. to divide. Over the past four decades, rising inequalities have been accompanied by a doubling of the poverty rate. If a post-Thatcherite or post-neoliberal change were to occur now, we would expect to see clear steps to counter these trends in inequality and poverty.

A key element in a more effective fight against poverty must be a major restructuring of the benefit system. Next year is the 80th anniversary of Beveridge 1942 Report, yet at least three of its five giants – misery, ignorance and misery – have not yet been abolished. Despite a slight change to the universal credit system in last month’s budget, Britain’s social security system is still petty, uneven and punitive. In some ways, the dark shadow of Victorian “poor law”, more anti-poor than anti-poverty, remains a key driver of modern social policy. The number of people applying for social assistance is still lower than in most other European countries, while in the last decade more than five million state sanctions were imposed on benefit claimants, two-thirds of whom were left with no income. At one point, the Ministry of Work and Pensions was impose more fines through local employment centers than the traditional court system.


Source link

]]>
Should you be excited about the 25% return on equity of public joint-stock company Magnit (MCX: MGNT)? https://atrx.net/should-you-be-excited-about-the-25-return-on-equity-of-public-joint-stock-company-magnit-mcx-mgnt/ Thu, 11 Nov 2021 03:33:45 +0000 https://atrx.net/should-you-be-excited-about-the-25-return-on-equity-of-public-joint-stock-company-magnit-mcx-mgnt/ While some investors are already familiar with financial metrics (hat tip), this article is for those who want to learn more about return on equity (ROE) and why it is important. To keep the lesson grounded in practicality, we will use ROE to better understand Magnit of the public joint stock company (MCX: MGNT). Return […]]]>

While some investors are already familiar with financial metrics (hat tip), this article is for those who want to learn more about return on equity (ROE) and why it is important. To keep the lesson grounded in practicality, we will use ROE to better understand Magnit of the public joint stock company (MCX: MGNT).

Return on equity or ROE is a test of how effectively a company increases its value and manages investor money. In other words, it reveals the company’s success in turning shareholders’ investments into profits.

See our latest review for Magnit

How to calculate return on equity?

Return on equity can be calculated using the formula:

Return on equity = Net income (from continuing operations) ÷ Equity

So, based on the above formula, Magnit’s ROE is:

25% = ₽45b ÷ ₽182b (Based on the last twelve months up to September 2021).

The “return” is the profit of the last twelve months. This therefore means that for each RUB1 of the investments of its shareholder, the company generates a profit of RUB0.25.

Does Magnit have a good ROE?

By comparing a company’s ROE with its industry average, we can get a quick measure of its quality. However, this method is only useful as a rough check, as companies differ a lot within a single industry classification. As you can see in the graph below, Magnit has an above-average ROE (14%) for the supermarket sector.

MISX: MGNT Return on Equity November 11, 2021

This is what we love to see. However, keep in mind that a high ROE does not necessarily indicate efficient profit generation. Besides changes in net income, high ROE can also be the result of high leverage to equity, which indicates risk. You can see the 2 risks we have identified for Magnit by visiting our risk dashboard for free on our platform here.

Why You Should Consider Debt When Looking At ROE

Businesses generally need to invest money to increase their profits. The money for the investment can come from the profits of the previous year (retained earnings), from the issuance of new shares or from loans. In the first two cases, the ROE will capture this use of capital to grow. In the latter case, the debt used for growth will improve returns, but will not affect total equity. In this way, the use of debt will increase the ROE, even if the basic economy of the business remains the same.

Magnit’s debt and its 25% ROE

It appears that Magnit is using a huge volume of debt to fund the business, as his debt-to-equity ratio is extremely high at 3.46. His ROE is decent, but once I consider all the debt I’m not really impressed.

Summary

Return on equity is a useful indicator of a company’s ability to generate profits and return them to shareholders. In our books, the highest quality companies have a high return on equity, despite low leverage. If two companies have the same ROE, then I would generally prefer the one with the least amount of debt.

But when a company is of high quality, the market often offers it up to a price that reflects that. The rate at which earnings are likely to grow, relative to earnings growth expectations reflected in the current price, must also be considered. So I think it’s worth checking this out free analyst forecast report for the company.

But beware : Magnit may not be the best stock to buy. So take a look at this free list of interesting companies with high ROE and low debt.

This Simply Wall St article is general in nature. We provide commentary based on historical data and analyst forecasts using only unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell shares and does not take into account your goals or your financial situation. Our aim is to bring you long-term, targeted analysis based on fundamental data. Note that our analysis may not take into account the latest announcements from price sensitive companies or qualitative documents. Simply Wall St has no position in the mentioned stocks.

Do you have any feedback on this item? Are you worried about the content? Get in touch with us directly. You can also send an email to the editorial team (at) simplywallst.com.


Source link

]]>
Hybrid Operating Room Market Analysis Report, Size, Share, Growth, Applications, Technology, Types, Products https://atrx.net/hybrid-operating-room-market-analysis-report-size-share-growth-applications-technology-types-products/ Sun, 07 Nov 2021 06:30:00 +0000 https://atrx.net/hybrid-operating-room-market-analysis-report-size-share-growth-applications-technology-types-products/ Emerging research logo Hybrid Operating Room Market Trends – Advances in Technology VANCOUVER, BC, CANADA, November 7, 2021 /EINPresswire.com/ – Hybrid Operating Room Market which provides in-depth Hybrid Operating Room market analysis and industry overview with respect to market size, market share, revenue growth, key companies, current trends and emerging market, recent technological and product […]]]>

Emerging research logo

Hybrid Operating Room Market Trends – Advances in Technology

VANCOUVER, BC, CANADA, November 7, 2021 /EINPresswire.com/ – Hybrid Operating Room Market which provides in-depth Hybrid Operating Room market analysis and industry overview with respect to market size, market share, revenue growth, key companies, current trends and emerging market, recent technological and product developments and comprehensive analysis, the report aims to offer a clear understanding of the market with respect to the key manufacturers, suppliers, vendors, distributors, and companies involved in the market. The report has been formulated through extensive primary and secondary research as well as verified and reliable data obtained from experts and industry professionals. The main findings of the report have been categorized into graphs, figures, tables and other illustrated representations.

The hybrid operating room market size is expected to reach USD 2,366.9 million at a stable CAGR of 12.4% in 2028, according to the latest analysis from Emergen Research. The increase in the number of surgical procedures and the growing adoption of minimally invasive surgeries are significantly driving the revenue growth of the market.

The Hybrid Operating Room (OR) is an advanced procedural space that combines the traditional operating room with an image-guided interventional suite. The combination allows the performance of very complex and advanced surgical procedures. Rooms and teams come together to meet the complex surgical needs of patients. These state-of-the-art spaces make it possible to combine image-guided surgeries with open procedures.

Hybrid operating rooms allow a smooth conversion from a minimally invasive surgery space to an open intervention space by providing the necessary capabilities and personnel in a single space. Hybrid operating rooms have also led to the development of new procedures, which offer patients with complex diseases broader options. Hybrid operating rooms allow surgeons to work efficiently for the best results. A variety of healthcare professionals work in hybrid operating rooms such as imaging professionals, surgeons and other specialists to ensure that complex patient needs are met more effectively

We have recent updates from the Hybrid Operating Room Market in a sample copy: https://www.emergenresearch.com/request-sample/703

It is important that the study on the Hybrid Operating Rooms market takes a closer look at the major players in the market and monitors the strategies that have enabled them to gain a solid foothold in the market. The performance of the product and services in different segments and geographies is carefully assessed during research. Apart from that, the research sheds light on real-time data on the opportunities that will completely transform the trajectory of the business environment in the years to come.

Leading Companies Operating in the Hybrid Operating Room Market and featured in the report are:

Toshiba Corporation, Stryker Corporation, Koninklijke Philips NV, Getinge AB, Mizuho Corporation, Siemens AG, Steris PLC, General Electric Company, Skytron LLC and Trumpf Medical.

It further offers comprehensive coverage of strategic alliances such as mergers and acquisitions, joint ventures, collaborations, product launches, brand promotions and partnerships, among others. Key strategic alliances for product development and advancement are expected to drive the market growth in the future. The report also covers an in-depth analysis of the major competitors in the market along with their growth strategies and business expansion plans.

Product search:

Thorough study of product and service application conducted by subject matter experts assessing Hybrid Operating Rooms market will help product owners to make sound decision. From analyzing what products companies should produce to how brands should position their product, the study covers everything business owners need to meet buyers’ demands.

Consult our prices @ https://www.emergenresearch.com/select-license/703

Emergen Research has segmented the global hybrid operating room market on the basis of component, application, end use, and region:

Components Outlook (Revenue, USD Million; 2018-2028)

Surgical instruments

Audiovisual display systems and tools

Intraoperative diagnostic imaging systems

Angiography systems

MRI systems

CT scanners

Other intraoperative diagnostic imaging systems

Operating room devices

Operating tables

Operating room lights

Surgical booms

Radiation shields

Other components

Application Outlook (Revenue, USD Million; 2018-2028)

Neurosurgery

Cardiovascular

Orthopedic

Thoracic

Others

End-Use Outlook (Revenue, USD Million; 2018-2028)

Hospitals and surgical centers

Outpatient surgery centers

The regional analysis of the Hybrid Operating Room market includes an analysis of the production and consumption ratio, demand and supply dynamics, regional trends and growth drivers, growth prospects, presence of key manufacturers and suppliers, as well as size and market share in key regions such as North America, Latin America, Europe, Asia-Pacific, Middle East and Africa. The report further offers key insights into the country-by-country analysis and the major factors driving the revenue growth of each regional market.

To learn more about the @ report https://www.emergenresearch.com/industry-report/hybrid-operating-room-market

Regional segmentation

North America (United States, Canada)

Europe (UK, Italy, Germany, France, rest of the EU)

Asia-Pacific (India, Japan, China, South Korea, Australia, rest of APAC)

Latin America (Chile, Brazil, Argentina, rest of Latin America)

Middle East & Africa (Saudi Arabia, United Arab Emirates, South Africa, Rest of MEA)

Request a customization of the report @ https://www.emergenresearch.com/request-for-customization/703

The subject matter experts leading the study are also taking a closer look at products in their stage of development and under development to help business owners conclude on business strategies that can lower their costs and promise great returns. or profits. The focus on new launches, acquisitions and mergers, collaboration, import and export status and supply chain management enables business evangelists, manufacturers and business owners to build a solid strategy when it comes to making an investment.

Key questions answered by the report:

Which region is expected to dominate the market in the coming years?

What are the recent technological and product advancements on the market?

What are the key strategies adopted by the major players in the Hybrid Operating Room market?

What are the main product types and applications in the Hybrid Operating Room industry?

What is the result of the SWOT analysis and Porter’s five forces analysis?

How is the Hybrid Operating Room Market competitive landscape?

Who are the key players in the sector?

What is the growth rate of the industry over the next few years?

How will the hybrid operating room market be valued by 2027?

Contents

Chapter 1. Methodology and sources

1.1. Market definition

1.2. Scope of research

1.3. Methodology

1.4. Research sources

1.4.1. Primary

1.4.2. Secondary

1.4.3. Paid sources

1.5. Market estimation technique

Chapter 2. Executive summary

2.1. Summary overview, 2020-2028

Chapter 3. Main information

Chapter 4. Hybrid Operating Room Market Segmentation and Impact Analysis

4.1. Hybrid Operating Room Materials Segmentation Analysis

4.2. Industrial outlook

4.2.1. Analysis of market indicators

4.2.2. Market driver analysis

4.2.2.1. Growing adoption of minimally invasive surgeries

4.2.2.2. Technological advances

4.2.3. Analysis of market constraints

4.2.3.1. Procedural risks associated with hybrid OR

4.3. Technological insights

4.4. Regulatory framework

4.5. Porter’s Five Forces Analysis

4.6. Competitive metric space analysis

4.7. Price trend analysis

4.8. Covid-19 impact assessment

Continued..!

Thanks for reading our report. The report can be customized as needed. Please contact us for more information and we will make sure you get the report that best suits your needs.

Watch the transcripts provided by Emergen Research

Spinal Implants and Surgical Devices Market https://www.emergenresearch.com/industry-report/spinal-implants-and-surgery-devices-market

Wound Care Market https://www.emergenresearch.com/industry-report/wound-care-market

Interventional Oncology Devices Market https://www.emergenresearch.com/industry-report/interventional-oncology-devices-market

Spinal Fusion Devices Market https://www.emergenresearch.com/industry-report/spinal-fusion-devices-market

Nerve Repair and Regeneration Market https://www.emergenresearch.com/industry-report/nerve-repair-and-regeneration-market

Shabaz Sayyed
Emerging research
1604757975
sales@emergenresearch.com
Visit us on social networks:
Facebook
Twitter
LinkedIn



Source link

]]>
Using statins may increase risk of diabetes, but reduce risk of CVD and death in rheumatoid arthritis https://atrx.net/using-statins-may-increase-risk-of-diabetes-but-reduce-risk-of-cvd-and-death-in-rheumatoid-arthritis/ Thu, 04 Nov 2021 13:21:26 +0000 https://atrx.net/using-statins-may-increase-risk-of-diabetes-but-reduce-risk-of-cvd-and-death-in-rheumatoid-arthritis/ This article was originally published on PratiqueCardiologie.com. A new study provides insight into the effects of statin therapy on the risk of diabetes and cardiovascular disease in patients with rheumatoid arthritis. Presented at the annual meeting of the American College of Rheumatology, study results indicate that initiation of statins was associated with a 32% reduction […]]]>

This article was originally published on PratiqueCardiologie.com.

A new study provides insight into the effects of statin therapy on the risk of diabetes and cardiovascular disease in patients with rheumatoid arthritis.

Presented at the annual meeting of the American College of Rheumatology, study results indicate that initiation of statins was associated with a 32% reduction in the risk of cardiovascular disease, a 54% reduction in the risk. all-cause mortality and a 33% increased risk of type 2 diabetes in patients with rheumatoid arthritis in a set of UK-based databases.

“We know that statins have been studied extensively in the general population, but our understanding of the effects of statins in patients with RA is limited and mainly based on a few studies. Since patients with RA already have a higher risk of CVD and type 2 diabetes compared to the general population, it is important to know the overall benefits and risks of statins, ”says Gulsen Ozen, MD, rheumatologist at the University of Nebraska Medical Center in Omaha. and co-author of the study, in a report.

Keen to develop a better understanding of the effects of statin initiation in patients with rheumatoid arthritis, Ozen and a team of colleagues from institutions across North America designed their study to examine related real-world data on initiation of statins using information from UK. Practice Research Datalink, Hospital Episode Statistics and Office of National Statistics databases. To be included in the prevalent cohort study of new users, patients had to be at least 18 years old with a diagnosis of rheumatoid arthritis and using at least 1 disease-modifying anti-rheumatic drug (DMARD) and no other diagnosis. from 1998-2018. Individuals were also required to have at least 1 year of baseline data available for analysis during the study period.

The statin initiators identified from the research were matched in a 1: 2 ratio to non-users based on temporal propensity scores (CST) which incorporated data including age, gender, BMI , smoking, alcohol, joint surgeries, history of cardiovascular disease, hypertension, rheumatic disease comorbidity index, osteoporosis and history of fracture, cancer, thyroid, chronic diseases of the liver, kidneys, lungs and other heart disease, healthcare utilization, DMARD, glucocorticoids, NSAIDs, and cardiovascular disease drugs.

The main outcome of interest for the study was cardiovascular disease outcomes, all-cause mortality, and type 2 diabetes. It should be noted that cardiovascular disease outcomes included myocardial infarction, stroke. , hospitalizations for heart failure and cardiovascular mortality. The presence of diabetes was based on diagnostic codes or on the prescription of diabetes treatment. The researchers emphasized that the risk of each outcome was assessed using Cox proportional hazards with adjustment for declines in TCPS and unbalanced patient characteristics after pairing.

The investigator’s initial search returned the records of 49,701 patients with a diagnosis of RA or a prescription for MRA. After applying the inclusion criteria, the investigators identified a total of 1,768 statin users and 3,528 non-users for inclusion in their analysis looking at cardiovascular disease and mortality and a total of 3,608 statin users and 7208 non-users for analysis looking at type 2 diabetes.

When assessing the incidence of cardiovascular disease, cardiovascular disease outcome was observed in 63 statin users and 340 non-users during the study period (3.0 per 100 person-years [PY] against 2.7 per 100 AP). When assessing the incidence of all-cause mortality, the results indicated that death occurred in 62 statin users and 525 non-users during the study period (2.7 per 100 AP against 4.1 per 100 AP). When assessing the incidence of diabetes, the results indicated that a new diagnosis of diabetes occurred among 128 statin users and 518 non-users (3.0 per 100 PA vs. 2.0 per 100 AP).

After analysis, the results suggested that initiation of a statin was associated with a 32% reduction in the risk of cardiovascular disease (RR: 0.68; 95% CI: 0.51-0.90), a 54% reduction in risk of all-cause mortality (RR: 0.46; 95% CI: 0.35-0.60) and 33% increase in risk of type 2 diabetes (RR: 1.33; 95% CI: 1.09-1.63). In addition, the results suggest that the NNT for preventing cardiovascular disease and 1-year mortality were 102 and 42, respectively, while the NNH for new diabetes was 127. Further analysis showed that patients with and without prior cardiovascular disease had similar reductions in the risk of cardiovascular disease (36% vs. 34%) and all-cause mortality (62% vs. 54%) with statin use.

“This may suggest that statins may have other beneficial effects in RA patients beyond lowering lipids. As rheumatologists, in addition to optimal control of disease activity, we must address the traditional risk factors for CVD in our patients in collaboration with their primary care providers. We believe our results emphasize the benefits of statins in patients with RA, ”added Ozen.

This study, “Reduction of cardiovascular disease and mortality versus risk of re-diabetes with statin use in patients with rheumatoid arthritis, ”Was presented at ACR Convergence 2021.


Source link

]]>
Robinson Pharma, Inc., Renew Life, Benefiber, Citrucel – The Host https://atrx.net/robinson-pharma-inc-renew-life-benefiber-citrucel-the-host/ Sun, 31 Oct 2021 09:28:28 +0000 https://atrx.net/robinson-pharma-inc-renew-life-benefiber-citrucel-the-host/ Introduction and scopeComprehensive approach applied to Fiber Supplements market analysis delivering valuable insight as well as factual evidence and actionable insights to clientele consisting of business investors, stakeholders, venture capitalists and entrepreneurs. The study compiles an array of data derived from in-depth, organic research crossing the critical complexities of the Fiber Supplements market. The data […]]]>

Introduction and scope
Comprehensive approach applied to Fiber Supplements market analysis delivering valuable insight as well as factual evidence and actionable insights to clientele consisting of business investors, stakeholders, venture capitalists and entrepreneurs. The study compiles an array of data derived from in-depth, organic research crossing the critical complexities of the Fiber Supplements market. The data offered in the market report is structurally organized and relevant to the industry, which represents an unbiased, decisive, and authentic report on the Keyword Market. The study deliverables encompass strategic perspective, revenue scales and models, industry valuations, demand-supply ratio, and cost structure of the Fiber Supplements market.

Landscape and supplier profiling:
Robinson Pharma, Inc.
Renew life
Beneficiary
Citrusel
Metamucil
Walgreens
Now
Optimal nutrition
BarnDadâ € ™ s
Myogenix
Twinlab
Garden of Life
SPECIES

We have recent fiber supplements market updates in the sample [email protected] https://www.orbisresearch.com/contacts/request-sample/6150963?utm_source=PoojaAD5

The study deliverables emphatically presents the growth inducing variables and their impact pathway to accelerate the growth of the Fiber Supplements market. Along with the growth stimulators, the market research describes the range of factors effectively hampering the growth of the market directly or indirectly. The growth fluctuations seen under the current Fiber Supplements market situation are effectively explained by the prevalence of recognized growth modifying factors. It also helps to estimate the possible opportunistic landscape describing the growth prospects as well as the potential emergence of challenges facing the Fiber Supplements market.

Market segmentation: fiber supplements market

Product-based segmentation:
Product type I, Product type II, Product type III

Segmentation based on applications:
Application I, Application II, Application III

Browse Complete Report With Facts & Figures Of Fiber Supplements Market Report At @ https://www.orbisresearch.com/reports/index/fiber-supplementss-market-2021-2028-emerging-growth-factors-trends-leading-players-and-in-depth-segmentation?utm_source=PoojaAD5

In addition, Growth Influencers, the study report also provides insightful assessment of key trends influencing the growth and opportunities for the Fiber Supplements market including industrial, non-industrial, economic, or demographic trends. In addition, technological megatrends are also assessed for their impact on modernizing the fiber supplements market. emerging market trends are assessed alongside current events around the world, such as the significant shift in business strategies following the onset of COVID-19, assessing the short and long term trends that have been defined by the accelerating pandemic a Substantial Change in Fiber Supplements Market Dynamics.

Regional assessment and diversification of segments.

North America (United States, Canada, Mexico)
Europe (UK, France, Germany, Spain, Italy, Central and Eastern Europe, CIS)
Asia Pacific (China, Japan, South Korea, ASEAN, India, rest of Asia-Pacific)
Latin America (Brazil, rest of LA)
Middle East and Africa (Turkey, CCG, Rest of Middle East)

By adding the conclusive research results, the market study targets major players at the epicenter of the Fiber Supplements market with market dominance and historical significance. The major prominent manufacturers of the Fiber Supplements Market are identified and further studied by assessing their major strengths and challenges. The study incorporates specific initiatives implemented to adapt to modernization trends in the industry, including the integration of new strategic concepts and the adoption of advanced technological systems to maximize productivity and ultimately fuel the growth of the industry. global fiber supplement market. The study highlights the latest industry events such as mergers and acquisitions of key importance in driving the growth of the market.

Highlights of the report
• The report includes country-specific growth projections of the Fiber Supplements industry over the next five years.
• Fiber supplement products or services by region request data.
• Regional insights into the fiber supplements market.
• Market share overview.
• Application and product information including revenue in millions of dollars from 2015 to 2025.
• Supply and demand analyzes are provided in the report.
• Value chain analysis and stakeholder analysis are provided in the study.
• The report covers major geographies including Eastern Europe, Western Europe, North America, Middle East, Africa and Asia Pacific.

Apply before purchase @ https://www.orbisresearch.com/contacts/enquiry-before-buying/6150963?utm_source=PoojaAD5

About Us:
Orbis Research (orbisresearch.com) is a one-stop shop for all of your market research needs. We have a large database of reports from leading publishers and authors around the world. We specialize in providing personalized reports according to the requirements of our clients. We have complete information about our publishers and are therefore confident of the correctness of the industries and verticals of their specialization. This helps our clients to map their needs and we produce the perfect market research required for our clients.

Contact us:
Hector Costello
Senior Manager Client Engagement
Central highway 4144N,
Office 600, Dallas,
Texas 75204, United States
Phone number: United States: +1 (972) -362-8199 | IND: +91 895 659 5155


Source link

]]>
Much smaller field, smaller ratio of young applicants https://atrx.net/much-smaller-field-smaller-ratio-of-young-applicants/ Sat, 30 Oct 2021 07:30:00 +0000 https://atrx.net/much-smaller-field-smaller-ratio-of-young-applicants/ Japanese voters in the Lower House elections on October 31 will have more say over who they want to control the government. This is due to the united front put in place by the opposition camp by backing a candidate in the vast majority of single-member districts up for grabs. This may translate into an […]]]>

Japanese voters in the Lower House elections on October 31 will have more say over who they want to control the government.

This is due to the united front put in place by the opposition camp by backing a candidate in the vast majority of single-member districts up for grabs.

This may translate into an increase in the presence of the opposition in the most powerful chamber and the ruling coalition made up of the Liberal Democratic Party and the predominant Komeito, but with a reduced majority. All opinion polls indicate that the coalition wins.

To offer more perspective on the possible outcome, The Asahi Shimbun analyzed the key figures to give a comparison with past voting trends.

The decision of the opposition parties to work together means that fewer candidates are in the running than at any time since the current electoral system was put in place in 1996.

Only 1,051 candidates are in the running, 129 fewer than in the last lower house elections in 2017.

In 217 of the 289 single-member constituencies, or 75% of the total, the five main opposition parties supported the same individual.

The Japanese Communist Party, almost always lonely in national elections, has also decided to team up with the other major parties, with the result that this time around it only presents 130 candidates, or about half of the 243 four years ago. years. The JCP has fielded between 170 and 330 candidates in all lower house elections since 1996.

The ruling coalition won two-thirds of the seats in the last lower house elections, as the opposition was very divided on the number of candidates to run.

The PLD’s victories in the 2017 and 2014 elections also created a large number of incumbents, which in turn increased the average age of candidates running this time around.

The average age of all applicants is 54.2 years, an increase of 1.4 years from four years ago.

There are only 99 applicants under 40, or 9.4% of the total. This figure is the lowest since 1996.

Conversely, there are 97 applicants aged 70 or over, or 9.2% of the total, the highest figure after 1996.

Among the successful candidates of the PLD in the elections of 2014 and 2017, the incumbents represented more than 90% of the total. One of the reasons for the low rate of young candidates this time around is the lack of opportunities for the younger generation to take over from a losing older candidate who then decides to retire from politics.

Another key figure to watch will be voter turnout.

The turnout in the 2014 elections was 52.66%, the lowest after the war. Although that figure rose slightly to 53.68% in the 2017 election, the greater number of head-to-head contests between candidates from the ruling coalition and one from the opposition bloc could result in a more participation this time around, as more competitive races are at stake.

Another factor that could also increase turnout is the relative novelty of Prime Minister Fumio Kishida as the new PLD leader after Yoshihide Suga resigned after just one year in office.

In the previous elections held under the leadership of a relatively new PLD leader, the turnout was higher than in the previous election. The 2000 Lower House election came about three months after Prime Minister Yoshiro Mori became the leader of the LDP and the turnout rose to 62.49%. Similarly, in the 1990 elections held about six months after Prime Minister Toshiki Kaifu took office, the turnout improved to 73.31%.

The October 31 lower house election will take place 27 days after Kishida, a former foreign minister, took office as prime minister.

(This article was written by Tatsuya Sato, Hiroki Koizumi, and Naoki Kikuchi.)

The Asahi Shimbun


Source link

]]>
Jobs available in Japan in September increase ahead of economic recovery https://atrx.net/jobs-available-in-japan-in-september-increase-ahead-of-economic-recovery/ Fri, 29 Oct 2021 02:03:45 +0000 https://atrx.net/jobs-available-in-japan-in-september-increase-ahead-of-economic-recovery/ People are seen commuting to work in Tokyo on October 8, 2021. (Mainichi) TOKYO (Kyodo) – Job availability in Japan improved for the first time in two months in September, with companies seeking staff ahead of economic recovery linked to government lifting of state of emergency COVID-19, government data showed on Friday. According to the […]]]>

People are seen commuting to work in Tokyo on October 8, 2021. (Mainichi)

TOKYO (Kyodo) – Job availability in Japan improved for the first time in two months in September, with companies seeking staff ahead of economic recovery linked to government lifting of state of emergency COVID-19, government data showed on Friday.

According to the Ministry of Health, Labor and Welfare, the job / candidate ratio fell to 1.16 against 1.14 the previous month, down 0.1 point compared to July. The ratio means that there were 116 job vacancies for every 100 job seekers.

Separate data from the Home Office and Communications Ministry showed that the seasonally adjusted unemployment rate in the reference month stood at 2.8%, unchanged from July.

Following a sharp drop in new coronavirus cases across the country, the country’s multi-month state of emergency was fully lifted on October 1. The measure at one point covered 21 of Japan’s 47 prefectures, including Tokyo.

As part of the emergency, people were urged to stay home, and restaurants and bars were told to close early and not to serve alcohol, hurting business confidence.

“The job availability figure showed employers tried to recruit more workers in anticipation of the economy picking up in October, especially among manufacturers and construction companies which suffered relatively minor damage from the industry. pandemic, “said Atsushi Takeda, chief economist of Itochu Research. Institute.

Meanwhile, the unemployment rate is yet to improve according to the job availability survey, as it surveys a wider range of sectors, including more service providers who have been hit hard during the pandemic. and remain cautious about hiring staff, Takeda said.

He added that some people were still refraining from looking for jobs in September over fears of another resurgence of the virus.

With the government promoting its vaccination campaign, the decrease in infections came after an explosive resurgence of the virus caused by the highly contagious Delta variant over the summer.

The latest data showed that the total number of working people fell by 280,000 from the previous month to 66.48 million, down for the second month in a row.

The number of unemployed fell by 20,000 from August to 1.89 million after increasing by 10,000 the previous month. Among them, 690,000 people voluntarily left their jobs, down by 50,000, while 540,000 were made redundant, up by 20,000, and 480,000 were new job seekers, down by 10,000.

By industry, the number of workers, unadjusted for seasonal factors, continued to grow in the telecommunications, medical and social sectors, up 8.4% and 2.3% year-on-year. previous to record the 19th and 14th consecutive monthly increases, respectively.

Figures for sectors hit hard by the pandemic remain sluggish, with accommodation and food service providers dropping 8.4% and the lifestyle and entertainment services sector plunging 11.0%.

Looking ahead, Takeda said the unemployment rate “may temporarily rise” as the number of vacancies and job seekers is expected to increase dramatically after the virus emergency ends.

“Even if the number is up, it’s a sign of economic recovery, so we shouldn’t take it negatively,” he said.


Source link

]]>